Novoste Outlines Plan To Weather Coming Flood Of Drug-Coated Stents

Novoste will acquire several new vascular intervention products to sustain its sales force in 2003 and 2004, when new drug-coated stents are expected to quell demand for the company's Beta-Cath coronary brachytherapy system, the firm reported Jan. 10 at the JP Morgan Healthcare Conference in San Francisco